Scholarlink

Background <p>The clinical value of induction chemotherapy (IC) in stage III-IV oropharyngeal squamous cell carcinoma (OPSCC) remains controversial. While randomized trials have shown limited survival benefit in unselected populations, it remains unclear whether IC provides benefit in high-risk subgroups and whether early treatment response to IC can serve as a prognostic and stratification tool.</p> Methods <p>We conducted a two-center retrospective real-world cohort study of 496 patients with stage III-IV OPSCC treated with definitive radiotherapy with or without IC. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics, adjusting for age, sex, smoking, alcohol use, T/N stage (AJCC 7th), tumor subsite, HPV status, clinical extranodal extension (cENE), and use of concurrent chemoradiotherapy. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) were compared using Kaplan-Meier and Cox proportional hazards models. A clinical nomogram was developed to predict individual DMFS and estimate IC benefit. In IC-treated patients, analyses were stratified by HPV status and IC response further stratified prognosis across endpoints.</p> Results <p>In IPTW-weighted multivariable Cox analysis, IC was independently associated with improved DMFS (HR = 0.60, 95% CI: 0.43–0.83, <i>p</i> = 0.016) and PFS (HR = 0.66, 95% CI: 0.49–0.90, <i>p</i> = 0.041). Subgroup analysis revealed reduced distant metastasis with IC in N3 patients (HR = 0.43, 95% CI: 0.20–0.93, <i>p</i> = 0.033). The nomogram (C-index = 0.697) suggested IC-associated benefit in patients with higher baseline risk. Among IC-treated patients, treatment response further stratified prognosis in an HPV-dependent manner. In the HPV-negative subgroup, patients achieving a complete or partial response (CR/PR) to IC experienced significantly improved OS compared with non-responders (<i>p</i> = 0.019). In multivariable analysis, IC response (CR/PR) was independently associated with superior PFS and LRFS, whereas no response-associated survival benefit was observed in HPV-positive patients.</p> Conclusion <p>In this real-world cohort of locally advanced OPSCC, IC was not associated with an overall survival benefit after adjustment, but was associated with improved distant metastasis-free survival, particularly in selected high-risk patients. Early IC response further identified a favorable-risk subgroup among HPV-negative patients. Given the retrospective design and treatment heterogeneity, these findings should be considered hypothesis-generating and require prospective validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Induction chemotherapy for locally advanced OPSCC: real-world evidence and HPV-dependent prognostic value of treatment response

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Gulidanna Shayan,
  • Ruichen Li,
  • Ya Liu,
  • Junlin Yi,
  • Yi Zhu,
  • Ye Zhang

摘要

Background

The clinical value of induction chemotherapy (IC) in stage III-IV oropharyngeal squamous cell carcinoma (OPSCC) remains controversial. While randomized trials have shown limited survival benefit in unselected populations, it remains unclear whether IC provides benefit in high-risk subgroups and whether early treatment response to IC can serve as a prognostic and stratification tool.

Methods

We conducted a two-center retrospective real-world cohort study of 496 patients with stage III-IV OPSCC treated with definitive radiotherapy with or without IC. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics, adjusting for age, sex, smoking, alcohol use, T/N stage (AJCC 7th), tumor subsite, HPV status, clinical extranodal extension (cENE), and use of concurrent chemoradiotherapy. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) were compared using Kaplan-Meier and Cox proportional hazards models. A clinical nomogram was developed to predict individual DMFS and estimate IC benefit. In IC-treated patients, analyses were stratified by HPV status and IC response further stratified prognosis across endpoints.

Results

In IPTW-weighted multivariable Cox analysis, IC was independently associated with improved DMFS (HR = 0.60, 95% CI: 0.43–0.83, p = 0.016) and PFS (HR = 0.66, 95% CI: 0.49–0.90, p = 0.041). Subgroup analysis revealed reduced distant metastasis with IC in N3 patients (HR = 0.43, 95% CI: 0.20–0.93, p = 0.033). The nomogram (C-index = 0.697) suggested IC-associated benefit in patients with higher baseline risk. Among IC-treated patients, treatment response further stratified prognosis in an HPV-dependent manner. In the HPV-negative subgroup, patients achieving a complete or partial response (CR/PR) to IC experienced significantly improved OS compared with non-responders (p = 0.019). In multivariable analysis, IC response (CR/PR) was independently associated with superior PFS and LRFS, whereas no response-associated survival benefit was observed in HPV-positive patients.

Conclusion

In this real-world cohort of locally advanced OPSCC, IC was not associated with an overall survival benefit after adjustment, but was associated with improved distant metastasis-free survival, particularly in selected high-risk patients. Early IC response further identified a favorable-risk subgroup among HPV-negative patients. Given the retrospective design and treatment heterogeneity, these findings should be considered hypothesis-generating and require prospective validation.